Market Overview

UPDATE: Zacks Downgrades Pure Bioscience to Neutral from Outperform on Commercialization Delays


Zacks downgraded Pure Bioscience (NASDAQ: PURE) from Outperform to Neutral with a $1.75 price target.

Zacks said, "[W]e are concerned about the slow sales ramp for the Company s SDC products. Although its lead product PURE Hard Surface is increasingly gaining recognition, sales may take longer time to gain traction since PURE is still in its early stage of commercialization of its SDC technology. Sales so far have not been impressive. SDC technology is quite new to most customers in the disinfectant market, and the costs for SDC are also higher than those for most existing technologies. Therefore, rollout of the SDC platform will take time."

Pure Bioscience closed at $0.79 on Thursday.

Latest Ratings for PURE

Dec 2012DowngradesOutperformNeutral

View More Analyst Ratings for PURE
View the Latest Analyst Ratings

Posted-In: ZacksAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (PURE)

View Comments and Join the Discussion!

Latest Ratings

XGNCantor FitzgeraldInitiates Coverage On18.0
LOOPRoth CapitalInitiates Coverage On14.0
FNDLoop CapitalMaintains46.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

TiVo Rallies on Goldman Initiation

Options Activity in Junk Bond ETF Could be a Negative Sign